ArticleHLA2025
The Hunt for HLA-DQ Allogeneic Eplets Is Not Over: Four New Ones, Including a Cross-Chain Eplet.
Article in HLA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The target of an anti-HLA antibody is an epitope on the surface of the antigen, and in particular the polymorphic eplet of its core, which contains one or a few polymorphic residues accessible to the molecule surface. The HLA Eplet Registry database references more than 550 HLA eplets thus deduced from AA sequence alignments. However, not all eplets have yet been verified and this list is not exhaustive. We performed a systematic analysis of sequence alignment of DQ antigens, to identify polymorphic amino acids so far not proposed as candidate eplets. From this, we describe and validate 3 DQB1 eplets targeted by sera of organ-transplanted patients and explore a new eplet overlapping the DQA1*03 and DQB1*03 chains. Serum antibody profiles using LABScreen, Lifecodes and a complementary DQ Luminex single antigen bead panel all showed a concordant pattern incriminating these residues. Moreover, antibodies were adsorbed and eluted using human splenic mononuclear cells and HLA-DQ transfected murine cell clones, thereby validating these four eplets. Their localisation by 3D modelling revealed uncertain accessibility of some residues implicated. The protrusion and accessibility of an eplet on the HLA surface may ultimately not always be sufficient to predict antibody binding, since the dynamic flexibility of the molecule can modify these parameters. Our strategy, combining Luminex single antigen assays, cell adsorption/elution and in silico prediction of surface exposure, altogether concur to ascertaining the realness of candidate eplets in the highly complex HLA system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.